Pipeline

Visepegenatide Injection (PB-119) is a once-weekly injectable long-acting GLP-1 receptor agonist, independently developed by PegBio as a Class 1 new drug. It holds global intellectual property rights and is a major innovative drug project under China's 13th Five-Year Plan. Visepegenatide Injection is primarily used as a first-line treatment for type 2 diabetes and obesity. Among domestically produced GLP-1 products in China, it is the only one that has completed Phase I and Phase II clinical trials in the United States and has been proven to have no ethnic differences in efficacy.

Visepegenatide Injection (PB-119) is a once-weekly injectable long-acting GLP-1 receptor agonist, independently developed by PegBio as a Class 1 new drug. It holds global intellectual property rights and is a major innovative drug project under China's 13th Five-Year Plan. Visepegenatide Injection is primarily used as a first-line treatment for type 2 diabetes and obesity. Among domestically produced GLP-1 products in China, it is the only one that has completed Phase I and Phase II clinical trials in the United States and has been proven to have no ethnic differences in efficacy.

Visepegenatide Injection (PB-119) is a once-weekly injectable long-acting GLP-1 receptor agonist, independently developed by PegBio as a Class 1 new drug. It holds global intellectual property rights and is a major innovative drug project under China's 13th Five-Year Plan. Visepegenatide Injection is primarily used as a first-line treatment for type 2 diabetes and obesity. Among domestically produced GLP-1 products in China, it is the only one that has completed Phase I and Phase II clinical trials in the United States and has been proven to have no ethnic differences in efficacy.

Visepegenatide Injection (PB-119) is a once-weekly injectable long-acting GLP-1 receptor agonist, independently developed by PegBio as a Class 1 new drug. It holds global intellectual property rights and is a major innovative drug project under China's 13th Five-Year Plan. Visepegenatide Injection is primarily used as a first-line treatment for type 2 diabetes and obesity. Among domestically produced GLP-1 products in China, it is the only one that has completed Phase I and Phase II clinical trials in the United States and has been proven to have no ethnic differences in efficacy.

Visepegenatide Injection (PB-119) is a once-weekly injectable long-acting GLP-1 receptor agonist, independently developed by PegBio as a Class 1 new drug. It holds global intellectual property rights and is a major innovative drug project under China's 13th Five-Year Plan. Visepegenatide Injection is primarily used as a first-line treatment for type 2 diabetes and obesity. Among domestically produced GLP-1 products in China, it is the only one that has completed Phase I and Phase II clinical trials in the United States and has been proven to have no ethnic differences in efficacy.

Visepegenatide Injection (PB-119) is a once-weekly injectable long-acting GLP-1 receptor agonist, independently developed by PegBio as a Class 1 new drug. It holds global intellectual property rights and is a major innovative drug project under China's 13th Five-Year Plan. Visepegenatide Injection is primarily used as a first-line treatment for type 2 diabetes and obesity. Among domestically produced GLP-1 products in China, it is the only one that has completed Phase I and Phase II clinical trials in the United States and has been proven to have no ethnic differences in efficacy.

Visepegenatide Injection (PB-119) is a once-weekly injectable long-acting GLP-1 receptor agonist, independently developed by PegBio as a Class 1 new drug. It holds global intellectual property rights and is a major innovative drug project under China's 13th Five-Year Plan. Visepegenatide Injection is primarily used as a first-line treatment for type 2 diabetes and obesity. Among domestically produced GLP-1 products in China, it is the only one that has completed Phase I and Phase II clinical trials in the United States and has been proven to have no ethnic differences in efficacy.

PB-718 is a novel long-acting GLP-1/GCG dual receptor agonist primarily designed for the treatment of obesity and MASH.Through dual activation of both GLP - 1 receptor and glucagon(“GCG”) receptor, PB - 718 is designed to achieve a synergistic effect that surpasses the efficacy of either receptor agonist alone, characterized by significant weight loss and reduced appetite.PB-718 had completed a Phase I clinical trial in the United States, which demonstrated its safety profile in healthy participants, and was undergoing a Phase Ib/IIa clinical trial in China for the treatment of obesity.

PB-718 is a novel long-acting GLP-1/GCG dual receptor agonist primarily designed for the treatment of obesity and MASH.Through dual activation of both GLP - 1 receptor and glucagon(“GCG”) receptor, PB - 718 is designed to achieve a synergistic effect that surpasses the efficacy of either receptor agonist alone, characterized by significant weight loss and reduced appetite.PB-718 had completed a Phase I clinical trial in the United States, which demonstrated its safety profile in healthy participants, and was undergoing a Phase Ib/IIa clinical trial in China for the treatment of obesity.

We are developing PB-1902, an oral, selective opioid receptor antagonist under clinical development in China for OIC. It is designed to effectively alleviate opioid-induced bowel dysfunction without diminishing the central pain-relieving effects of opioids, rendering PB-1902 a potentially optimal treatment option for OIC.

PB-722 is a GCG receptor agonist, for the treatment of congenital hyperinsulinemia. PB-722 has been granted the Orphan Drug Designation by the FDA and has demonstrated its safety in several animal models and its efficacy in raising and maintaining blood glucose levels in a hypoglycemic animal model.In May 2023, the NMPA approved our IND application to conduct clinical trial of PB-722 for the treatment of congenital hyperinsulinemia in China, rendering PB-722 the first drug candidate with IND approval for the treatment of congenital hyperinsulinemia in China.

PB-2301 is our preclinical-stage drug candidate. It has the potential to become the best-in-class GLP-1/GIP dual receptor agonist.

PB-2309 is our preclinical-stage drug candidate. It has the potential to become the best-in-class GLP-1/GIP/GCG triple dual receptor agonist.